{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:45:51Z","timestamp":1787507151848,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T00:00:00Z","timestamp":1569024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.alit.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T20:01:59Z","timestamp":1572292919000},"page":"268-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study"],"prefix":"10.1016","volume":"69","author":[{"given":"Michihiro","family":"Hide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Vardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2019.08.012_bib1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM199606203342510","article-title":"Hereditary angioedema","volume":"334","author":"Cicardi","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2019.08.012_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2796.1997.76893000.x","article-title":"Type I hereditary angio-oedema. Variability of clinical presentation and course within two large kindreds","volume":"241","author":"Winnewisser","year":"1997","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.alit.2019.08.012_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1572-0241.2006.00492.x","article-title":"Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency","volume":"101","author":"Bork","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.alit.2019.08.012_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2019.08.012_bib5","unstructured":"Kalm\u00e1r L, Heged\u00fbs T, Tordai A. HAEdb. C1 Inhibitor Gene Mutation Database. http:\/\/hae.enzim.hu\/index.php. [Accessed 5 July 2019]."},{"key":"10.1016\/j.alit.2019.08.012_bib6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2019.08.012_bib7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1172\/JCI200214211","article-title":"Increased vascular permeability in C1 inhibitor\u2013deficient mice mediated by the bradykinin type 2 receptor","volume":"109","author":"Han","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2019.08.012_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/WOX.0b013e318279affa","article-title":"WAO guideline for the management of hereditary angioedema","volume":"5","author":"Craig","year":"2012","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.alit.2019.08.012_bib9","first-page":"1215","article-title":"[WAO guideline for the management of hereditary angioedema]","volume":"64","author":"Craig","year":"2015","journal-title":"Arerugi"},{"key":"10.1016\/j.alit.2019.08.012_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(92)90661-M","article-title":"Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin)","volume":"210","author":"Rhaleb","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.alit.2019.08.012_bib11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/all.12244","article-title":"Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study","volume":"68","author":"Ba\u015f","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2019.08.012_bib12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2019.08.012_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","article-title":"Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial","volume":"107","author":"Lumry","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2019.08.012_bib14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/cei.12358","article-title":"Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial","volume":"177","author":"Malbran","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.alit.2019.08.012_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2332\/allergolint.12-RAI-0471","article-title":"Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research \u2013 secondary publication","volume":"61","author":"Horiuchi","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2019.08.012_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.anai.2015.03.010","article-title":"Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan","volume":"114","author":"Ohsawa","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2019.08.012_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/all.12303","article-title":"Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema","volume":"69","author":"Aberer","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2019.08.012_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaip.2016.09.023","article-title":"Subcutaneous icatibant for the treatment of hereditary angioedema attacks: comparison of home self-administration with administration at a medical facility","volume":"5","author":"Otani","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2019.08.012_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cpdd.138","article-title":"Pharmacokinetics of single and repeat doses of icatibant","volume":"4","author":"Leach","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.alit.2019.08.012_bib20","unstructured":"Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s): Icatibant. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022150Orig1s000ClinPharmR.pdf. [Accessed 5 July 2019]."},{"key":"10.1016\/j.alit.2019.08.012_bib21","unstructured":"Shire plc. Shire Receives Approval of FIRAZYR\u00ae (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan. https:\/\/globenewswire.com\/news-release\/2018\/09\/21\/1574147\/0\/en\/Shire-Receives-Approval-of-FIRAZYR-icatibant-injection-for-the-Treatment-of-Hereditary-Angioedema-HAE-Attacks-in-Japan.html. [Accessed 5 July 2019]."}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893019301571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893019301571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:10:48Z","timestamp":1761156648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893019301571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1323893019301571"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2019.08.012","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}